Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age5-17
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Purpose : the aim of this study is to assess the feasibility and safety of ultrasound-induced opening of the blood-brain barrier (BBB) with the SonoCloud-9 implantable ultrasound device in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor treated with carboplatin.

Study hypothesis : the blood-brain barrier can be transiently and safely opened with pulsed low intensity ultrasound immediately prior to intravenously delivered chemotherapy. The opening of the BBB with the SonoCloud-9 system will increase the tumor exposure to carboplatin and increase progression-free and overall survival in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor.

Eligibility criteria

Qualifiers

patient aged ≥ 5 years old and < 18 years old

patient able to receive sonications and perform MRI studies without sedation

diagnosis of supra-tentorial primary malignant brain tumor (e.g. malignant glioma, embryonal tumor including ATRT, ependymoma)

recurrence or progression of brain tumor after at least a first line of standard treatment (multifocal tumors and metastatic disease allowed)

Disqualifiers

weight <15kg

significant intra-tumoral bleeding (hematoma) or ipsilateral subdural effusion

6 weeks for nitrosoureas

1 month for temozolomide

Trial design

Treatments tested in this trial

  • SonoCloud® (9 transducers)

Treatment groups

24 Participants
are divided into 1 treatment group

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

CarThera

Collaborator

Gustave Roussy, Cancer Campus, Grand Paris

Collaborator

Institut Curie

Collaborator

URC-CIC Paris Descartes Necker Cochin

Collaborator